Current and Emerging Treatment Landscape of mHSPC

Jack Andrews MD; Eugene Cone, MD; and Arash Rezazadeh, MD, discuss how metastatic hormone-sensitive prostate cancer presents clinically, explore current treatment standards including combination therapies, evaluate emerging data from the ARANOTE trial on darolutamide efficacy, consider quality of life factors in treatment selection, and examine how novel therapeutic approaches may reshape future care pathways.Timecodes1:54 mHSPC and Imaging4:57 Current SOC in mHSPC10:15 Choosing Therapy in mHSPC18:51 ARANOTE Trial in mHSPC21:15 Experience With ARI27:08 Emerging mHSPC Treatments32:51 ARANOTE Subgroup Analysis35:31 Future Outlook for mHSPC